DYAI
Dyadic International, Inc.
NASDAQ · USHealthcareBiotechnology
$1.21-3.97%
Price as of Jul 20, 2026
DYAI growth
Dyadic International, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -11.0%
- EBITDA
- -29.1%
- EBIT
- -22.7%
- EPS
- -7.9%
- Free cash flow
- -18.8%
- Operating cash flow
- -18.8%
Forward estimates
- Revenue
- +125.5%
- EBITDA
- +2.1%
- EPS
- +95.3%
Three-year CAGR
- Revenue
- -25.1%
- EBITDA
- -28.4%
- EBIT
- -21.1%
- Net income
- -26.8%
- EPS
- -15.0%
- Free cash flow
- -43.5%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.